Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling regimens for hair loss, with users discussing needle lengths and frequencies. One user reports noticeable improvement at the crown using 1mm weekly, while another uses Keto shampoo with dermastamping.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The user reported hair regrowth using microneedling with a Dr.Pen Ultima M8 over six months, without additional treatments like minoxidil or finasteride. They followed a schedule of varying needle depths and noted lifestyle changes to reduce stress.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The user shared progress pictures after a year of treating hair loss with 5% minoxidil, then a combination of minoxidil/finasteride topical, and microneedling at 1.5mm bi-weekly. They plan to switch to oral finasteride and more frequent microneedling at a shallower depth while continuing the current regimen.

The post and conversation are about a user's progress with microneedling and minoxidil for hair loss. The user is happy with the progress and plans to continue with the treatment, without using finasteride.

User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

A user discusses their rapidly receding hairline and a prescribed topical solution containing 7% Minoxidil, 0.1% Finasteride, and 3% biotinoyl tripeptide. The solution is a custom compound from their dermatologist, costing $50 for a one-month supply.

A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user inquires if RENU Biogen is a DHT inhibitor.

The user applied 5% minoxidil twice daily and microneedled approximately 1.5 times a month. They noticed some progress in hair growth, though they were unsure if it was due to treatment or hair length.

The user cannot tolerate oral finasteride and is considering topical finasteride, minoxidil, microneedling, and RU58841 as alternative treatments for hair loss. They seek advice on whether these options are worth trying.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

Microneedling for hair loss without using Minoxidil, finasteride, or RU58841. Users discuss experiences and effectiveness of microneedling alone.

The post discusses using microneedling alone for hair regrowth without finasteride or minoxidil due to side effects and dependency concerns. The user is also considering the "Zix" formula, acetic acid, topical zinc solutions, and lithium chloride.

Microneedling for hair loss is discussed, with users suggesting different frequencies and needle lengths, such as 1.5mm every 3 to 6 weeks or 1.0mm weekly. Some users recommend less frequent sessions to avoid scalp damage and soreness.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

Slow, steady progress on hair loss treatments such as finasteride, minoxidil, microneedling and Nizoral; the need for patience when using these treatments over a period of months or years; and how to deal with discouragement due to slow progress.